齐拉西酮注射液治疗儿童精神分裂症急性激越症状35例

Ziprasidone injection on treatment of acute agitation symptoms in childhood schizophrenia: a clinical study of 35 cases

目的探讨齐拉西酮注射液治疗儿童精神分裂症患者急性激越症状的临床效果及安全性。方法采用随机数字表法将符合《国际疾病分类(第10版)》(ICD-10)精神分裂症诊断标准的有急性激越症状的70例儿童患者分为实验组和对照组各35例,实验组给予齐拉西酮注射液,对照组给予氟哌啶醇注射液,疗程3天。于治疗前、治疗后2、12、24、48、72h分别采用阳性和阴性症状量表(PANSS)减分率、临床疗效总评量表(CGI)评定疗效,治疗结束时采用副反应量表(TESS)评定安全性。结果疗程结束时实验组和对照组PANSS评分减分率分别为46.92%、49.46%,临床好转率分别为77.14%、80.00%,两组疗效比较差异均无统计学意义(P>0.05);实验组和对照组不良反应发生率分别为20.00%、37.14%,差异有统计学意义(P<0.05)。结论齐拉西酮注射液对有急性激越症状的儿童精神分裂症患者的疗效与氟哌啶醇相当,不良反应发生率较低。

Objective To investigate the clinical efficacy and safety of Ziprasidone injection on the therapy of acute agitation symptom of childhood schizophrenia. Methods 70 subjects with acute agitation symptoms conform to ICD- 10 for schizophrenia were randomly assigned into two groups,the research group( n = 35) were given ziprasidone injection,and the control group( n = 35) were given haloperidol injection for 3 days. Before and after treatment 2,12,24,48,72 h of the respectively Positive and Negative Syndrome Scale( PANSS) reduction rate,the end of the Clinical Global Impression Scale( CGI) were assessed. At the end of the treatment,the Treatment Emergent Symptom Scale( TESS) was assessed. Results At the end of the treatment,PANSS reduction rate was46. 92% in the research group and the control group was 49. 46%,the clinical improvement rate was 77. 14% in the research group and the control group was 80. 00%. No statistically significant differences between the two groups were found on efficacy( P > 0. 05).Adverse effects rate in the research group was 20. 00%,the control group was 37. 14%,there was significant difference between the two groups( P < 0. 05). Conclusion Ziprasidone injection is effective and haloperidol rather in treating the acute agitation symptoms of childhood schizophrenia,the rate of extrapyramidal adverse reaction was low.